USFDA-RRA for Vadodara facility of Alembic Pharmaceuticals completed with no observations

29 Aug 2022 , 02:53 PM

Alembic Pharmaceuticals Limited informed that the Company successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Vadodara-based Bioequivalence Facility, Bio-analytical division, with no observations.

The RRA was conducted from August 22, 2022, to August 26, 2022.

Alembic Pharmaceuticals Ltd. is a multinational pharmaceutical firm based in Vadodara, India. It is involved in the production of pharmaceutical goods, pharmaceutical ingredients, and pharmaceutical intermediates. In India, it is also regarded as a market leader in the macrolides sector of anti-infective medications.

At around 2.57 PM, the stock of Alembic Pharmaceuticals was trading at Rs649.60 per piece, down by 0.12% from its previous closing of Rs650.40 on the BSE. The scrip touched intraday high and low of Rs662.15 and Rs642.85 respectively.

For feedback and suggestions, write to us at [e-mail]